X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Are injectables lucrative for Indian Pharma? - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Dec 19, 2012

    Are injectables lucrative for Indian Pharma?

    As the patent cliff nears, the generic companies are working out ways to fuel their top lines. In this, the injectable market has been an area of interest for various companies. Besides Indian generic companies, global generic companies too are entering this segment. For example, Novartis' generic arm Sandoz acquiring Ebewe, which is an injectable focused company.

    Opportunity in the injectable market

    The overall size of the injectable market during 2009 was approx US$ 200 bn. This has grown further by 10% to US$ 220 bn in 2011 with generic penetration being 15%. In the injectable group, the segments of biologics and oncology are relatively more lucrative offering higher upside.

    US, being the world's largest pharmaceutical industry, also accounts for the largest chunk of the overall injectable space. During 2011, US had 38% share in the injectable market of which generic penetration was at US$ 5 bn. It is expected that by 2015 roughly 75 products worth US$ 16 bn could face the entry of generics for the first time. It is also estimated that US generic injectable sales would grow at a CAGR of 10% in the period 2012-2015.

    Source: Sandoz

    How do injectable drugs differ from the others?

    The current strict compliance with respect to manufacturing facilities has resulted in a limited number of injectable manufacturing facilities globally. Due to this, the US too has witnessed strong shortage of injectable products on the back of warning letters issued to many companies and recall of drugs. The number of injectables falling under shortage list increased from 39 to 139 in 2011. By nature manufacturing injectable drugs is complex involving long lead time.

    Historically, the generic approval per injectable has been as low as one. Further, large part of the injectables segment has faced limited competition i.e. around 86% of the products have less than 5 players. This is because majority of the injectables further fall under niche segments like biosimilars and oncology. Thus, overall owing to high entry barriers with longer manufacturing and approval times and limited competition, this segment offers lucrative margins. All these aspects have increased consolidation, some of major ones being - Hospira acquiring Orchid's injectable segment, Novartis acquiring Ebewe and Mylan acquiring Bioniche among others.

    Where do Indian companies stand in this space?

    Among the Indian companies, Cadila has entered into a JV with Hospira for oncology injectables. The company has widened its portfolio and will be incurring capex of US$ 20 m for new products. On the other hand Strides Arcolab, has been a distinctively injectable focused player. The company too has entered into JV and has one division which focuses only on injectable shortages that take place in the US. Sun Pharma too has launched some injectables in the oncology space. Dr Reddy's acquisition of Octoplus Pharma has also been done to tap specialty injectables. Claris Life Science is one more injectable focused company, which recently entered into JV with Otsuka. Biocon has entered into a partnership with Mylan for manufacturing of drugs in the biosimilar segment.

    Our view...

    Given the intense competition and price erosion evident in the US generics segment, Indian generics players have been increasingly focusing on niche segments and Para IV opportunities to bolster revenues and profits from this market. And the injectables segment is one such niche area. Thus, those companies having injectables as part of their portfolios have the potential to improve margins and report decent growth. However, there is a flipside too. Owing to the complexities in manufacturing in this space, the norms are quite strict when it comes to compliance with good manufacturing practices. Case in point is Hospira's. The company too derived considerable revenues from injectables. But a warning letter from the USFDA negatively impacted the company. Overall, a right mix of injectable products in the portfolio, backed by appropriate manufacturing activities will add value to the overall growth of companies.

      Bhavita Nagrani (Research Analyst) is a Chartered Financial Analyst (ICFAI) with nearly six years of experience in the field of equity research. She has a deep understanding of the global as well as the domestic Healthcare industry and keenly tracks the developments therein. When it comes to stock investing, she is a strong advocate of the bottom-up approach to stock picking and has a remarkable ability to discern nuances in the business models of companies belonging to the same industry. Bhavita is the contributor to our large cap franchise, StockSelect.

     

     

    Equitymaster requests your view! Post a comment on "Are injectables lucrative for Indian Pharma?". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SUN PHARMA SHARE PRICE


    Aug 17, 2017 12:11 PM

    TRACK SUN PHARMA

    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SUN PHARMA 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE SUN PHARMA WITH

    MARKET STATS